Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Joly

Showing results (11-20 of 345) with videos related to

Pageof 35
Sort By:
Bulletin Du Cancer|September 13, 2007
[Prognostic factors of localised, locally advanced or metastatic prostate cancer]Florence Joly, Michel Henry-Amar
Journal of Geriatric Oncology|January 27, 2021
Geriatric phone follow-up including validated cognitive assessment in older patients treated for cancerMarie Lange, Giulia Binarelli, Florence Joly
Bulletin Du Cancer|March 31, 2015
[Management of side effects of targeted therapies in renal cancer: sexual disorders]Thomas Bessede, Florence Joly, Thierry Lebret
JCO Precision Oncology|January 20, 2022
PARP Inhibitor in Advanced Endometrial Carcinoma Beyond <i>BRCA</i> and Related Genetic MutationsJérôme Alexandre, Isabelle Ray-Coquard, Florence Joly
Bulletin Du Cancer|March 31, 2015
[Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines]Bernard Escudier, Florence Joly, Jean-Charles Soria
Psycho-Oncology|January 22, 2011
Cognitive dysfunction and cancer: which consequences in terms of disease management?Florence Joly, Olivier Rigal, Sabine Noal, et al.
Oncogene|September 21, 2004
Disruption of E2F signaling suppresses the INK4a-induced proliferative defect in M33-deficient miceNathalie Coré, Florence Joly, Annie Boned, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 4, 2011
Postchemotherapy residual masses in nonseminomatous germ cell tumor patients: 18F-FLT PET is unlikely to identify mature teratoma, but imaging of alphav beta3 integrin expression couldFlorence Joly, Maria Paciencia, Catherine Bor, et al.
British Journal of Clinical Pharmacology|August 11, 2015
Oral antineoplastic agents: how do we care about adherence?Marie Barillet, Virginie Prevost, Florence Joly, et al.
Bulletin Du Cancer|January 30, 2026
[Gineco group guidelines for clinical practice in gynecological cancer, Nice-Saint-Paul de Vence 2024-2025]Jean-Sébastien Frenel, Isabelle Ray-Coquard, Florence Joly
Pageof 35

Showing results (11-20 of 345) with videos related to

Sort By:
Pageof 35
Bulletin Du Cancer|September 13, 2007
[Prognostic factors of localised, locally advanced or metastatic prostate cancer]Florence Joly, Michel Henry-Amar
Journal of Geriatric Oncology|January 27, 2021
Geriatric phone follow-up including validated cognitive assessment in older patients treated for cancerMarie Lange, Giulia Binarelli, Florence Joly
Bulletin Du Cancer|March 31, 2015
[Management of side effects of targeted therapies in renal cancer: sexual disorders]Thomas Bessede, Florence Joly, Thierry Lebret
JCO Precision Oncology|January 20, 2022
PARP Inhibitor in Advanced Endometrial Carcinoma Beyond <i>BRCA</i> and Related Genetic MutationsJérôme Alexandre, Isabelle Ray-Coquard, Florence Joly
Bulletin Du Cancer|March 31, 2015
[Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines]Bernard Escudier, Florence Joly, Jean-Charles Soria
Psycho-Oncology|January 22, 2011
Cognitive dysfunction and cancer: which consequences in terms of disease management?Florence Joly, Olivier Rigal, Sabine Noal, et al.
Oncogene|September 21, 2004
Disruption of E2F signaling suppresses the INK4a-induced proliferative defect in M33-deficient miceNathalie Coré, Florence Joly, Annie Boned, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 4, 2011
Postchemotherapy residual masses in nonseminomatous germ cell tumor patients: 18F-FLT PET is unlikely to identify mature teratoma, but imaging of alphav beta3 integrin expression couldFlorence Joly, Maria Paciencia, Catherine Bor, et al.
British Journal of Clinical Pharmacology|August 11, 2015
Oral antineoplastic agents: how do we care about adherence?Marie Barillet, Virginie Prevost, Florence Joly, et al.
Bulletin Du Cancer|January 30, 2026
[Gineco group guidelines for clinical practice in gynecological cancer, Nice-Saint-Paul de Vence 2024-2025]Jean-Sébastien Frenel, Isabelle Ray-Coquard, Florence Joly
Pageof 35